Quantcast

Latest Rhinitis Stories

2010-07-09 15:39:00

AUSTIN, Texas, July 9 /PRNewswire/ -- Lake levels are higher and the normally brown Austin roadside is green and lush, but for allergy sufferers summer showers can increase their exposure to allergenic mold spores. Molds can be found inside and outside the home. Along with pollens from trees, grasses, and weeds, molds are an important trigger of allergic rhinitis, affecting nearly 40 million Americans, according to the American Academy of Allergy, Asthma & Immunology (AAAAI). "Mold...

2010-06-28 13:54:00

ANTONY, France, June 28, 2010 /PRNewswire-FirstCall/ -- After having announced positive results for the first year of its phase IIb/III clinical trial (VO 57.07) conducted on Actair(R) sublingual allergen immunotherapy tablets in allergic rhinitis triggered by house dust mites in April 2009, Stallergenes S.A. today announces the results of the second year of this study. Following this first year which demonstrated positive results for both the dosages tested (300 IR[1] and 500 IR)...

2010-06-24 03:59:33

Research shows Pycnogenol decreases nasal and ocular symptoms in allergic rhinitis patients An estimated 60 million people in the U.S. are affected by allergic rhinitis, commonly known as hay fever, according to the American Academy of Allergy Asthma and Immunology. Hay fever is an allergic inflammation of the nasal airways that causes itching, swelling, mucus production, hives and rashes. A study published in the June 14, 2010 issue of Phytotherapy Research demonstrates...

2010-06-21 01:46:00

ANTONY, France, June 21, 2010 /PRNewswire-FirstCall/ -- Stallergenes S.A. announces the results of a phase III clinical trial (VO55.06) conducted in China aimed at assessing the efficacy and safety of sublingual immunotherapy (Staloral(R) mites 300) in adult patients suffering from asthma triggered by house dust mites. Study VO55.06 is a phase III randomized, double-blind, placebo-controlled study conducted over a period of 15 months in 14 centers located in China's main cities....

2010-06-07 07:28:00

LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Data published at the European Allergy, Asthma & Clinical Immunology (EAACI) congress in London today documents that GRAZAX(R) is the only allergy immunotherapy tablet (AIT) to show sustained disease control 2 years after treatment completion. Leading specialists emphasise the relevance of the data with regard to inclusion in guidelines for treatment of grass pollen allergy. Traditional symptomatic medications, such as antihistamine...

2010-05-25 08:33:00

CARY, N.C., May 25 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), announced today that it has more Environmental Exposure Chambers (EECs), or allergy models for recreating environmental conditions than any other CRO. Over the past nine years, Cetero has used these models in more than 40 clinical studies to help its pharmaceutical partners develop novel therapies for a wide range of anti-allergic small molecule drugs, immunotherapies,...

2010-04-19 01:44:00

ANTONY, France, April 19, 2010 /PRNewswire-FirstCall/ -- Stallergenes S.A. today announced the first results of a phase III clinical trial (VO61.08) conducted in the USA on its sublingual grass pollen immunotherapy tablet, Oralair(R). This phase III study is the first clinical study in the USA to be conducted by Stallergenes as part of the Oralair(R) clinical development which already encompassed 4 phase III clinical trials conducted in Europe. This development program has so far...

2010-03-19 11:37:00

FT. WASHINGTON, Pa., March 19 /PRNewswire/ -- Allergy sufferer and actress Alison Sweeney today joined the makers of the fastest 24-hour over-the-counter (OTC) allergy medicine, ZYRTEC®, for an unusual race to officially welcome the first day of spring and new ZYRTEC® Liquid Gels. The "Race Against Your Allergies," which took place in New York City's Madison Square Park, featured some unusual runners - six, five-foot-tall noses representing some of...

2010-03-15 15:34:00

MISSISSAUGA, ON, March 15 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that it has enrolled the first patient in its European Phase 2 clinical trial evaluating WF10 as a treatment for allergic rhinitis....

2010-03-10 07:57:00

BRIDGEWATER, N.J., March 10 /PRNewswire/ -- Sanofi-aventis U.S. today announced the launch of the Clean Sweep campaign to help guide spring cleaning for the estimated 60 million Americans who are affected by nasal allergies. This campaign helps them locate lurking allergens in their homes and improve their allergy management routine. According to a Spring Cleaning Survey of more than one thousand adults, 94 percent of respondents recognized that proper cleaning can help reduce incidences of...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related